Natural products represent an inexhaustible source of novel therapeutic agents. Their complex and constrained three-dimensional structures endow these molecules with exceptional biological properties, thereby giving them a major role in drug discovery programs. However, the search for new bioactive metabolites is hampered by the chemical complexity of the biological matrices in which they are found. The purification of single constituents from such matrices requires such a significant amount of work that it should be ideally performed only on molecules of high potential value (i.e., chemical novelty and biological activity). Recent bioinformatics approaches based on mass spectrometry metabolite profiling methods are beginning to address the complex task of compound identification within complex mixtures. However, in parallel to these developments, methods providing information on the bioactivity potential of natural products prior to their isolation are still lacking and are of key interest to target the isolation of valuable natural products only. In the present investigation, we propose an integrated analysis strategy for bioactive natural products prioritization. Our approach uses massive molecular networks embedding various informational layers (bioactivity and taxonomical data) to highlight potentially bioactive scaffolds within the chemical diversity of crude extracts collections. We exemplify this workflow by targeting the isolation of predicted active and nonactive metabolites from two botanical sources (Bocquillonia nervosa and Neoguillauminia cleopatra) against two biological targets (Wnt signaling pathway and chikungunya virus replication). Eventually, the detection and isolation processes of a daphnane diterpene orthoester and four 12-deoxyphorbols inhibiting the Wnt signaling pathway and exhibiting potent antiviral activities against the CHIKV virus are detailed. Combined with efficient metabolite annotation tools, this bioactive natural products prioritization pipeline proves to be efficient. Implementation of this approach in drug discovery programs based on natural extract screening should speed up and rationalize the isolation of bioactive natural products.

With the aim of isolating structurally original natural products, a molecular networking (MN)-based prioritisation approach has been developed and applied to a collection of 292 plant extracts. It led to the selection of a sample-specific cluster of ions detected in the bark extract of Codiaeum peltatum. The MN-guided purification of the targeted compounds afforded four unprecedented chlorinated monoterpenyl quinolones named chloroaustralasines A–C and isochloroaustralasine A. Faced with inconsistent spectral data of some previously reported quinolones, the total synthesis of the corresponding dihydroxy and chlorohydrin compounds was undertaken. The desired products were obtained in three steps, allowing the structural reassignment of two erioaustralasines. The chloroperoxidase-mediated hydroxychlorination reaction developed for the synthesis of the chlorinated quinolone showed that such complex molecules could be good substrates for this enzyme and, at the same time, raised the question of the biosynthetic origin of the non-artefactual chlorohydrin moiety.

In continuation of our efforts to find new antimalarial drugs, a systematic in vitro evaluation using a chloroquine resistant strain of Plasmodium falciparum (FcB1) was undertaken on extracts prepared from various parts of Vietnamese plants. The ethyl acetate extract obtained from the stem bark of Artocarpus styracifolius (Moraceae) exhibited strong antiplasmodial activity (87 % at 10 µg/mL) whereas weak cytotoxicity was observed in a human fibroblast cell line (MRC-5). Phytochemical investigation of this extract led to isolation of two new prenylated flavonoids, styracifolins A and B (1 and 2), as well as the known artoheterophyllin A (3) and B (4), artonins A (5), B (6), and F (7), and heterophyllin (8). Structures of 1 and 2 were elucidated by spectroscopic methods and through comparison with data reported in the literature. Compounds 1–8 exhibited antiplasmodial activities with IC₅₀ values ranging from 1.1 µM to 13.7 µM, and compounds 1, 2, 6, and 8 showed significant antitrypanosomal activities.

In an effort to find potent inhibitors of the protein kinases DYRK1A and CDK1/Cyclin B, a systematic in vitro evaluation of 2,500 plant extracts from New Caledonia and French Guyana was performed. Some extracts were found to strongly inhibit the activity of these kinases. Four aristolactams and one lignan were purified from the ethyl acetate extracts of Oxandra asbeckii and Goniothalamus dumontetii, and eleven aporphine alkaloids were isolated from the alkaloid extracts of Siparuna pachyantha, S. decipiens, S. guianensis and S. poeppigii. Among these compounds, velutinam, aristolactam AIIIA and medioresinol showed submicromolar IC₅₀ values on DYRK1A.